Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-03-18 Sale |
2025-03-20 4:32 pm |
CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer |
4,025 | $0.599 | $2,411 | 135,725 (Direct) |
View |
| 2023-04-18 Sale |
2023-04-19 4:07 pm |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer |
2,532 | $6.5749 | $16,648 | 140,676 (Direct) |
View |
| 2023-01-10 Sale |
2023-01-11 4:05 pm |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer |
7,825 | $5.24 | $41,003 | 143,208 (Direct) |
View |
| 2022-04-19 Sale |
2022-04-21 4:04 pm |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer |
4,062 | $35.37 | $143,673 | 151,033 (Direct) |
View |
| 2022-01-11 Sale |
2022-01-13 4:05 pm |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development |
3,965 | $48.51 | $192,340 | 121,793 (Direct) |
View |
| 2021-12-10 Sale |
2021-12-13 5:53 pm |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development |
7,500 | $51.46 | $385,948 | 230,758 (Direct) |
View |
| 2021-04-16 Sale |
2021-04-20 4:00 pm |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development |
3,275 | $83.3 | $272,809 | 64,800 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-04 Option Award |
2025-02-06 5:55 pm |
N/A 2035-02-03 |
CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer |
466,500 | $0 | 492,750 (Direct) |
View |
| 2024-01-18 Option Award |
2024-01-19 8:37 pm |
N/A 2034-01-17 |
CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer |
223,750 | $0 | 223,750 (Direct) |
View |
| 2023-07-19 Option Award |
2023-07-20 5:18 pm |
N/A 2033-07-18 |
CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer |
375,000 | $0 | 375,000 (Direct) |
View |
| 2023-02-06 Option Award |
2023-02-07 4:13 pm |
N/A 2033-02-05 |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer |
425,000 | $0 | 425,000 (Direct) |
View |
| 2022-01-25 Option Award |
2022-01-27 4:37 pm |
N/A 2032-01-24 |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer |
86,360 | $0 | 208,153 (Direct) |
View |
| 2021-12-10 Exercise |
2021-12-13 5:53 pm |
N/A N/A |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development |
7,500 | $16.32 | 230,758 (Direct) |
View |
| 2021-12-10 Exercise |
2021-12-13 5:53 pm |
N/A 2029-04-15 |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development |
7,500 | $0 | 230,758 (Direct) |
View |
| 2021-11-19 Option Award |
2021-11-22 5:38 pm |
N/A N/A |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development |
60,958 | $0 | 125,758 (Direct) |
View |
Ownership |
2021-04-02 4:32 pm |
N/A N/A |
FATE THERAPEUTICS INC | FATE | Chu Yu-Waye See Remarks |
0 | $0 | 277,426 (Direct) |
View |